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Paradoxical activation of Raf by a novel Raf inhibitor 
Clare A Hall-Jackson’, Patrick A Eyersl, Philip Cohen’, Michel Goedert*, 
F Tom Boyle3, Neil Hewitt3, Helen Plant3 and Philip Hedge3 
Background: Raf is a proto-oncogene that is activated in response to growth 
factors or phorbol esters, and is thought to activate MAP kinase kinase-1 
(MKKl) and hence the classical MAP kinase (MAPK) cascade. 
Results: The compound ZM 336372 is identified as a potent and specific 
inhibitor of Raf isoforms in vitro. Paradoxically, exposure of cells to ZM 336372 
induces > 1 OO-fold activation of c-Raf (measured in the absence of compound), 
but without triggering any activation of MKKI or p42 MAPK/ERKP. The 
ZM 336372-induced activation of c-Raf occurs without any increase in the 
GTP-loading of Ras and is not prevented by inhibition of the MAPK cascade, 
protein kinase C or phosphatidylinositide 3-kinase. ZM 336372 does not 
prevent growth factor or phorbol ester induced activation of MKKl or p42 
MAPWERKIZ, or reverse the phenotype of Ras- or Raf-transformed cell lines. 
The only other protein kinase inhibited by ZM 336372 out of 20 tested was 
SAPK2Ip38. Although ZM 336372 is structurally unrelated to SB 203580, a 
potent inhibitor of SAPK2/p38, the mutation of Thrl OG+Met made 
SAPK2lp38 insensitive to ZM 336372 as well as to SB 203580. 
Conclusions: Raf appears to suppress its own activation by a novel feedback 
loop, such that inhibition is always counterbalanced by reactivation. These 
observations imply that some agonists reported to trigger the cellular activation 
of c-Raf might actually be inhibitors of this enzyme, and that compounds which 
inhibit the kinase activity of Raf might not be useful as anticancer drugs. The 
binding sites for ZM 336372 and SB 203580 on Raf and SAPK2/p38 are 
likely to overlap. 
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Introduction 
The sustained activation of the classical mitogen-activated 
protein (MAP) kinase cascade is believed to play a critical 
role in inducing the proliferation of some cells and the dif- 
ferentiation of others [l]. In this pathway, growth factors 
trigger the dimerisation and activation of their receptors 
leading to transphosphorylation of the receptors at several 
tyrosine residues [Z]. These phosphotyrosines then inter- 
act with proteins containing SH2 domains, two of which 
are the ‘adaptors’ Grb2 and She [3--S]. Grb2 is complexed 
to the guanine nucleotide exchange factor mSos that acti- 
vates Ras [6,7]. Thus the binding of Grb2 to phosphory- 
lated receptors (and/or to the tyrosine phosphorylated 
form of She, which is bound to these receptors) recruits 
mSos from the cytosol to the plasma membrane where it 
converts Ras from the inactive GDP-bound form to the 
active GTP-bound state [8]. 
Ras is associated with the plasma membrane by virtue of 
lipid modifications at its carboxyl terminus and its mem- 
brane localisation is essential for activation by growth 
factors [9]. GTP-Ras interacts with the protein kinase 
c-Raf, localising the latter to the plasma membrane 
[lo-121 where it becomes activated by a mechanism(s) 
that is not yet fully understood [13]. The activation of 
c-Raf is then thought to induce the sequential activation 
of MAP kinase kinase-1 (MKKl) and the MAP kinases 
p44 MAPK and ~42 MAPK (also known as ERKl and 
ERKZ) that, in turn, activate other protein kinases, such as 
MAPK-activated protein kinase-1 (MAPKAP-Kl, also 
known as Rsk). When activation of the MAPKs is sus- 
tained, they translocate from the cytosol to the nucleus to 
regulate transcriptional events that are thought to be criti- 
cal for proliferation or differentiation (14-171. 
Inappropriate activation of the MAP kinase cascade can 
lead to the uncontrolled proliferation or differentiation of 
cells, and the mutation or overexpression of components of 
the MAP kinase cascade is a common feature of many 
cancer cells. For example, the epidermal growth factor 
(EGF) receptor is overexpressed or mutated in many 
cancers of epithelial origin, the platelet-derived growth 
factor (PDGF) receptor in cancers of mesenchymal or glial 
origin and the nerve growth factor (NGF) receptor in 
prostate cancer and prostate hyperplasia (reviewed in [18]). 
Ras is mutated to an activated, oncogenic form in a high 
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proportion of human cancers [19], c-Raf is the cellular 
homologue of a viral oncogene [ZO], and the overexpres- 
sion and hyperactivation of MAP kinase in a number of 
breast cancers has been reported [Zl]. For these reasons, 
specific inhibitors of different components of these path- 
ways might have therapeutic potential as anticancer 
agents. Indeed, drugs that inhibit the EGF receptor and 
the PDGF receptor are undergoing human clinical trials, 
and farnesyl transferase inhibitors have been developed 
that prevent the activation of Ras. In the MAP kinase 
cascade itself, a compound (PD 98059) has been identified 
that interacts with MKKl and prevents its activation by c- 
Raf [Z]. This compound can reverse the transformed phe- 
notype of several Ras-transformed cell lines [23]. 
Here, we describe a compound (ZM 336372) that is a 
potent inhibitor of the protein kinase c-Raf in vitro. Para- 
doxically, however, incubation of mammalian cells with 
this compound induces an enormous activation of c-Raf 
and the B-Raf isoform (measured in the absence of the 
drug), suggesting that a feedback control loop exists by 
which Raf isoforms suppress their own activation. This 
unexpected finding may explain why ZM 336372 does not 
reverse the phenotype of Ras-transformed cell lines, and 
suggests that inhibition of the kinase activity of Raf might 
not be a good approach for the development of an anti- 
cancer drug. 
Results 
Identification of ZM 336372 as an inhibitor of c-Raf 
ZM 336372 (Figure 1) was identified by screening a com- 
pound library with a single step coupled in vitro kinase 
cascade assay that measured the phosphorylation of 
myelin basic protein (MBP) in the presence of c-Raf, 
GST-MKKl and GST-p42 MAPK [24]. The c-Raf had 
been activated by cotransfection in Sf9 insect cells with 
v-Ras and Lck and was added without purification. 
Because of the sensitivity of the assay, the Sf9 cell 
extracts were used at 50,000-fold dilution or greater [24]. 
Control Sf9 lysates were used to demonstrate that incor- 
poration of radioactivity into MBP was dependent on the 
activity of c-Raf. In order to determine the molecular 
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The effect of ZM 336372 on c-Raf activity in vitro. (a) Human c-Raf 
(open circles) or human B-Raf (closed circles) were activated in Sf9 
cells by cotransfection from baculovirus vectors containing DNA 
encoding v-Ras and Lck in the absence of ZM 336372. The cell lysates 
were then assayed for c-Raf activity in the absence or presence of the 
indicated concentrations of ZM 336372. (b) c-Raf was activated in 
mouse Swiss 3T3 cells by incubation for 2 min with 100 nglml EGF or 
0.4 ug/ml PMA (open circles), in human 293 cells by incubation for 
2 min with 100 rig/ml EGF or 0.4 ug/ml PMA (closed circles) or in Sf9 
cells (open triangles) by coexpression with DNA encoding v-Ras and 
Lck. ZM 336372 was excluded from these incubations. The c-Raf 
activity was then assayed in the absence or presence of the indicated 
concentrations of ZM 336372 after its immunoprecipitation from the 
cell lysates. The data obtained after stimulation with EGF or phorbol 
esters were combined because the IC,, values for c-Raf were identical. 
The results are presented relative to control incubations in which ZM 
336372 was omitted (mean f SEM for three separate experiments). 
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target of ZM 336372, each kinase was subsequently 
assayed individually in the presence of the inhibitor. The 
inhibitor was found to have no discernible effect on either 
the ability of MKKl to phosphorylate ~42 MAPK or the 
ability of p42 MAPK to phosphorylate MBP, even at con- 
centrations as high as 100 pM. Similarly, the compound 
did not inhibit a coupled in vitro kinase cascade assay 
involving MKKl, p42 MAPK and MBP, in which MKKl 
had previously been activated by c-Raf or mutated to a 
constitutively active form by changing Ser218 and Ser222 
to glutamic acid. These data unambiguously identified 
c-Raf as the only kinase in the primary coupled kinase 
screen that was inhibited by the compound over a 
lOOO-fold concentration range. 
Selectivity of ZM 336372 as a Raf inhibitor 
ZM 336372 is a potent inhibitor of human c-Raf. The IC,, 
value was 0.07 pM in the standard assay (Figure 2a), which 
contains 0.1 mM ATP. The IC5, decreased to 0.01 l.tM at 
0.025 mM ATP and increased to 0.9 pM at 2.5 mM ATP 
(data not shown) indicating that ZM 336372 is a competitive 
inhibitor with respect to ATP. The compound inhibited 
Table 1 
Effect of 50 pful ZM 336372 on the activities on protein kinases 
in vitro. 
Protein kinase Activity (Vo control) 
Protein kinase A 56f2 
Protein kinase BCL 92 + 2 
Protein kinase C 92-+2 
AMPK 102+6 
MAPKAP kinase 1 B 86f6 
MAPKAP kinase 2 93 + 7 
MAPKAP kinase 3 89f2 
p70 S6 kinase 99fl 
CK2 111 f2 
p42 MAPK 105-+5 
MKKl 99 Ik 2 
GSK3/3 10322 
MKK4 86f8 
SAPKl /JNK 102fl 
SAPK3 102+3 
SAPK4 92+5 
Cyclin B/CDKl 106_+4 
SAPK2a 3-+2 
SAPKPb 12fl 
The protein kinases were incubated for 10 min at 4°C in the presence 
or absence of 50 pM ZM 336372 and then assayed for activity at 
30°C in the presence of 0.1 mM ATP. Activities are given as a mean 5 
SEM relative to control incubations in which the inhibitor was omitted. 
AMPK, AMP-activated protein kinase; MAPK, mitogen-activated 
protein kinase; MAPKAP, MAPK-activated protein; GSK3, glycogen 
synthase kinase-3; MKK, MAPK kinase; SAPK, stress-activated protein 
kinase; JNK, c-Jun N-terminal kinase; CK2, casein kinase-2; CDKl, 
cyclin-dependent protein kinase-1, also called cdc2. 
c-Raf tenfold more potently than B-Raf (Figure Za) and 
did not inhibit 17 of 19 other protein kinases tested, even 
at 50 pM (Table 1). The two exceptions were 
SAPK2alp38a and SAPKZb/p3@2 (Table l), both of 
which were inhibited by ZM 336372 with an IC,, of 2 PM 
under the assay conditions used. The effect of ZM 336372 
on SAPKZalp38a and SAPKZb/p3@2 activity is detailed 
at the end of the Results section. 
In the experiments shown in Figure 2a, c-Raf and B-Raf 
were assayed directly in Sl9 cell lysates. If c-Raf was 
assayed after its immunoprecipitation from the lysates of 
Sf9 cells, human 293 cells or mouse Swiss 3T3 cells, 
however, the IC,, values were tenfold higher (Figure Zb), 
indicating that interaction of c-Raf with the antibody 
decreases its affinity for the drug. The IC,, values were 
similar whether the 293 cells or the Swiss 3T3 cells were 
stimulated with EGF or phorbol 12,13 myristate acetate 
(PMA; see the legend to Figure 2). 
Failure of ZM 336372 to prevent the activation of MKKl or 
p42 MAPK in mammalian cells 
As c-Raf and B-Raf are believed to lie at the head of the 
classical MAP kinase cascade, we next examined 
whether ZM 336372 would prevent the activation of 
MKKI (an immediate downstream target of these 
enzymes) and ~4’2 MAPK in cells. Surprisingly, ZM 
336372 (even at 10 FM) only suppressed the EGF- 
induced activation of MKKl by 37%, and had no effect 





Effect of ZM 336372 on the activation of MKKl and p42 MAPK in 
Swiss 3T3 cells. Confluent Swiss 3T3 cells were incubated for 18 h in 
Dulbecco’s modified Eagles medium (DMEM) containing 0.5% fetal 
calf serum (FCS) and then for 60 min with or without 10 uM ZM 
336372 followed by stimulation for 5 min with 100 rig/ml EGF. The 
cells were lysed and MKKl and p42 MAPK activities measured after 
immunoprecipitation. The results are presented as mean f SEM for 
three separate experiments. 
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Effect of ZM 336372 on MAPK phosphorylation in HCT 116 cells. 
The figure shows a MAPK western blot of lysates from cells treated for 
16 h with: lane1 , 10 pM PD 98059; lane 2,50 PM PD 98059; lane 3, 
no compound control; lane 4, 10 FM ZM 336372 in the presence of 
10% FCS. 
also failed to affect the activation of ~42 MAPK induced 
by stimulating Swiss 3T3 cells with PMA or L6 cells 
with insulin-like growth factor-I (IGF-I; data not 
shown). Consistent with these observations, and unlike 
PD 98059 [23], ZM 336372 (10 FM) also failed to inhibit 
the constitutive activation of p44 MAPK or ~42 MAPK 
seen in the human colon tumour cell line HCT116 
(Figure 4) and H-ras transformed NIH3T3 cells (data 
not shown) and did not affect either the proliferation or 
morphology of NIH3T3 cells transformed by either 
overexpression of H-ras or constitutively activated c-Raf 
(Table 2). Moreover, unlike PD 98059, ZM 336372 was 
similarly unable to affect proliferation of untransformed 
NIH3T3 cells that had been stimulated by various mito- 
gens (Table 3). 
Paradoxical activation of c-Raf by ZM 336372 in 
mammalian cells 
In order to investigate why ZM 336372 did not prevent the 
activation of MKKl or ~42 MAPK, we exposed Swiss 3T3 
cells to ZM 336372 and then measured c-Raf activity in 
the absence of ZM 336372 after its immunoprecipitation 
from the cell lysates. These experiments revealed that 
exposure to ZM 336372 induced a remarkable activation of 
c-Raf that increased several hundredfold after 60 min and 
Table 2 
Effect of ZM 336372 on the growth and morphology of 
transformed NIH3T3 cells. 
10 WM ZM 336672 50 pM PD 98059 
(O/o control) (% control) 
Monolayer growth 
H-ras 3T3 46 8 
Raf 3T3 125 7 
Morphology 
H-ras 3T3 No effect Fully reverted 
Raf 3T3 No effect Fully reverted 
NIH3T3 cells transfected with H-ras or the catalytic domain of c-Raf 
were cultured for 6 days in 5% charcoal stripped serum in the 
presence of compound before scoring the effect on proliferation (cell 
number presented as percentage of untreated cells) and morphology, 
(scored relative to untransfomed NIH3T3 cells). 
Table 3 
Effect of ZM 336372 on the proliferation of NIH3T3 calls 
stimulated with various mitogens. 
10 FM ZM 336372 20 pM PD 98059 
Stimulus (o/o control) (% control) 
PDGF 45 24 
FGF 81 13 
LPA 99 1 
EGF 68 29 
Insulin 90 29 
Basal growth 115 -20 
NIH3T3 cells were cultured for 6 days in charcoal stripped medium, 
in the presence of 10 rig/ml PDGF, 10 nglml fibroblast growth factor 
(FGF), 10 PI/ml lysophosphatidic acid (LPA), 10 nglml EGF, 10 pglml 
insulin or media alone in order to determine the effect of compounds 
on growth factor stimulated and basal cell growth. 0.02 ml of 2.5 mM 
phenazine methosulphate was added to 1 ml of 1 mglml XTT (Sigma) 
and 0.125 ml of the mixture added to the culture medium of each 
dish of cells. After incubation for 2 h at 37”C, the absorbance at 
450 nm was measured. Values are presented as percent of that 
without compound. 
was sustained for at least 3 h (Figure Sa). The activation 
was much higher than that attained after stimulation with 
EGF (Figure .5a), which is the most potent inducer of c- 
Raf activation in Swiss 3T3 cells [Z]. However, ZM 
336372 did not itself induce any activation of p42 MAPK 
(Figures 3,Sa). In contrast, EGF potently induced p42 
MAPK activation irrespective of whether the Swiss 3T3 
cells had been preincubated with ZM 336372 (Figure 3). 
This was despite the fact that, after incubation of the cells 
for 1 h with ZM 336372, subsequent stimulation with EGF 
only increased the level of c-Raf activity by ZO-30% (data 
not shown). 
Similar results were obtained in several other cells. For 
example, incubation of monkey COSl cells or human 293 
cells for 1 h with 10 pM ZM 336372 also increased c-Raf 
activity over lOO-fold (data not shown) and the analogous 
experiment in PC12 cells increased B-Raf activity lOO-fold 
(data not shown). Under these conditions, ZM 336372 did 
not itself induce any activation of p42 MAPK in PC12 
cells, consistent with the results in other cells. 
In order to further demonstrate the effect of ZM 336372 
on c-Raf activity we preincubated NIH3T3 cells with 
compound for several hours and then observed the effect 
of removing ZM 336372 on MKKl and p42 MAPK. 
Removal of the inhibitor triggered an activation of MKKl 
and p42 MAPK (Figure Sb), implying that the cell does 
indeed contain high specific activity c-Raf that is pre- 
vented from activating its downstream substrate MKKl by 
the inhibitor. No activation of MKKl and p42 MAPK 
occurred in control experiments carried out in parallel in 
which ZM 336372 was omitted (data not shown). 
Mechanism of activation of c-Raf by ZM 336372 Figure 5 
The compound PD 98059, which binds to MKKl and pre- 
vents its activation by c-Raf (see the Introduction section), 
also stimulates the basal activity of c-Raf several-fold, as 
well as the rate and extent of c-Raf activation induced by 
PDGF [ZZ]. These findings suggest that activation of the 
classical MAP kinase pathway suppresses the activation of 
c-Raf. Incubation of Swiss 3T3 cells with 50 yM 
PD 98059, prevents the EGF- or PMA-induced activation 
of MAPKAP-Kl (Figure 6b), the most downstream com- 
ponent of the MAP kinase cascade. However, the activa- 
tion of c-Raf induced by ZM 336372 was only reduced by 
40-.500/o (Figure 6a). The activation of c-Raf by 
ZM 336372 is therefore largely independent of the activa- 









The activation of c-Raf by different agonists can result from 
the stimulation of several signal transduction pathways, 
including the activation of protein kinase C [13] or phos- 
phatidylinositide (PtdIns) 3-kinase [25]. The activation of 
c-Raf induced by ZM 336372, however, does not appear to 
occur via either of these pathways. Thus c-Raf activation 
was unaffected by Ro 318220 (Figure 6a), an inhibitor of 
protein kinase C and other protein kinases [26], under con- 
ditions where it suppressed the PMA-induced activation of 
p42 MAPK by 85% (data not shown). Similarly, an inhibitor 
of PtdIns 3-kinase (wortmannin), did not affect the activa- 
tion of c-Raf by ZM 336372 (Figure 6a) under conditions 
where the IGF-l-induced activation of protein kinase B in 
Swiss 3T3 cells was suppressed by 95% (data not shown). 
(b) 350 
The activation of c-Raf by growth factors, such as EGF, is 
dependent on the activation of Ras. In unstimulated wiss 
3T3 cells the percentage of GTP-Ras relative to 
GDP-Ras + GTP-Ras was 10.7 + 2.6%, which increased 
to 44 * 2.4% after stimulation for 2 min with EGF 
(Figure 7). After incubation for 60 min with ZM 336372 
(at which time c-Raf activation is maximal; Figure Sa), 
however, the proportion of GTP-Ras had not increased at 
all (9.5 * 1.8%) (Figure 7). Thus the activation of c-Raf by 
ZM 336372 does not result from an increase in the GTP- 
loading of Ras. In addition, pretreatment of Swiss 3T3 
cells for 120 min with ZM 336372, followed by washout of 
the compound as described in the legend to Figure Sb, did 
not cause any activation of Ras, despite the induced acti- 
vation of the MAP kinase cascade (data not shown). 
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Prolonged mitogenic stimulation leads to the hyperphos- 
phorylation of c-Raf that can be visualised by a reduction 
in its electrophoretic mobility, and prevented by incubat- 
ing the cells with PD 98059 [22]. Pretreatment of Swiss 
3T3 cells for 6-200 min with ZM 336372 did not change 
the electrophoretic mobility of c-Raf, as shown by 
immunoblotting (data not shown). These experiments 
also established that the level of c-Raf protein did not 
change over the duration of the experiment. 
Effect of ZM 336372 addition or removal on the activation of c-Raf 
and the MAPK cascade. (a) Confluent Swiss 3T3 cells were 
incubated for 18 h in DMEM containing 0.5% FCS and then treated 
for the times indicated with 10 pM ZM 336372 (closed circles) or 
100 nglml EGF (open circles) and the activity of c-Raf measured in 
the absence of ZM 336372 after its immunoprecipitation from the 
cell lysates. p42 MAPK was also immunoprecipitated from cell 
lysates following treatment with 10 PM ZM 336372 and its kinase 
activity assayed (open triangles). The results are presented as 
mean + SEM for three separate experiments. (b) NIH3T3 cells were 
incubated for 120 min in the presence of 10 PM ZM 336372 and 
0.5% FCS before washing the cells three times in Hanks buffered 
salt solution and replacing with fresh medium without compound. 
Cells were lysed at various times after compound washout and 
assayed for MKK (open circles) and MAPK (closed circles) activities. 
Results shown for each time point are based on raw data relative to 
each other for each kinase assayed. 
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Figure 6 * 
(a) 120 , 1 
PD 98059 - + - + - - 
ZM336372 - - + + + + 
Ro318220 - - - - + - 
Wortmannin - - - - - + 
(b) 
120-/ti 
EGF - + - - + - 
PMA - - + - - + 
PD 98059 - - - + + + 
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Effect of PD 98059, wortmannin and Ro 318220 on the activation of 
c-Raf by ZM 336372. (a) Confluent Swiss 3T3 cells were incubated in 
DMEM containing 0.5% FCS for 18 h and then pretreated with (+) or 
without (-) 50 uM PD 98059 (60 min), 100 nM wortmannin (10 min) or 
0.3 PM Ro 318220 (60 min) prior to incubation for 60 min with 10 uM 
ZM 336372 in the continued presence of these compounds. The 
activity of c-Raf was measured after immunoprecipitation from the cell 
lysates and the results are presented as a percentage of the activity 
measured after incubation for 60 min with ZM 336372 in the absence of 
any other compound. (b) Swiss 3T3 cells were cultured as for (a) 
except that cells were stimulated with 100 rig/ml EGF or 0.4 ug/ml PMA 
with (+) or without (-1 60 min pretreatment with 50 uM PD 98059. The 
activity of MAPKAP kinase-1 was measured after immunoprecipitation 
from the cell lysates and the results are presented as a percentage of 





EGF - - + + - - 
ZM336372 - - - - + + 
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Lack of effect of ZM 338372 on the GTP-loading of Ras in Swiss 3T3 
cells. Cells were labelled as described in the Materials and methods 
section before stimulation with 100 nglml EGF (2 min) or 10 uM 
ZM 336372 (60 min). Ras was immunoprecipitated from the cell 
lysates and the bound guanine nucleotides eluted and separated using 
thin-layer chromatography. The figure shows an autoradiograph of a 
representative experiment. The quantitation of these experiments is 
presented in the text. 
Mechanism of inhibition of c-Raf and SAPK2/p38 by 
ZM 336372 
The finding that ZM 336372 inhibits SAPKZalp38a and 
the closely related homologue SAPKZb/p3@2 (collectively 
termed SAPKZ/p38), as well as Raf (Table l), was intrigu- 
ing, because we have reported that SB 203580 (a relatively 
specific inhibitor of SAPKZ/p38) also inhibits c-Raf [27]. 
Although the structures of ZM 336372 (Figure 1) and SB 
203580 are completely different, these observations raised 
the possibility that the binding sites for ZM 336372 and 
SB 203580 were identical or at least overlapping. 
A residue that is critical for the interaction of SB 203580 
with SAPKZalp38a is Thr106, because the 4-fluorophenyl 
ring of this drug cannot be accommodated if a sidechain 
larger than threonine is present at this position. Thus we 
[28] and others [29,30] have shown that SAPKZ/p38 
becomes insensitive to SB 203580 if Thr106 is mutated to 
a residue with a more bulky sidechain, such as methionine 
or glutamine. The mutation of Thrl06+Met also abol- 
ished sensitivity of SAPKZalp38a or SAPKZb/p38PZ to 
ZM 336372 (Figure 8a,b). 
Other MAP kinase family members are insensitive to SB 
203580 because the position equivalent to ThrlO6 of 
SAPKZalp38a is occupied by methionine or glutamine, 
but these enzymes can be made sensitive to SB 203580 
by mutating this residue to threonine [28,30,31]. The 
results presented in Figure 8c,d showed that two other 
MAP kinase family members, SAPK3 and SAPK4, could 
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Figure 8 
Inhibition of wild-type and mutant 
(a) SAPK2a/p38cr, (b) SAPK2b/p38P2, 
(c) SAPK3 and (d) SAPK4 by ZM 336372. 
The effect of the drug on the wild-type 
enzymes is shown by the closed circles and 
its effect on mutant enzymes by open symbols. 
Mutations are designated using the single- 
letter amino acid code. SAPK2a/p38a and 
SAPK2blp38P2 are inhibited by ZM 336372 
with IC,, values of 2 PM. Mutation of 
Thrl OG+Met in SAPK2alp38a and 
SAPK2blp38S2 abolishes sensitivity to 
ZM 336372. SAPK3 and SAPK4 are resistant 
to ZM 336372 because they have methionine 
residues at positions 109 and 107 
respectively. Mutation of these residues to 
threonine makes these enzymes sensitive to 
the drug. Mutation to glycine of the amino acid 
at the position equivalent to Thr106 leads to 
an increase in the IC,, values in all four 
protein kinases. All mutants were generated, 
expressed, purified and activated as in [28]. 
Ia) 
120 , 
SAPK2a (W SAPKPb 
lZO- 
T106M 
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Concentration of ZM 336372 (,uM) Concentration of ZM 336372 (JIM) 
SAPKB W SAPK4 
120 
0 
0.1 1 10 100 0.1 1 10 100 
Concentration of ZM 336372 (PM) Concentration of ZM 336372 (yM) 
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be made sensitive to ZM 336372 by the same mutation. 
In the case of SB 203580, MAP kinases can be made 
even more sensitive to the drug by substituting even 
smaller residues, such as serine, alanine and glycine [28]. 
In contrast, however, mutation to these residues made 
SAPKZ/p38, SAPK3 and SAPK4 less sensitive to 
ZM 336372 than mutation to threonine (Figure 8, 
Table 4). 
Discussion 
In this paper we have identified a potent and specific 
inhibitor of c-Raf (ZM 336372) that shows a tenfold 
selectivity over B-Raf (Figure Za), a 30-fold selectivity 
over SAPKZ/p38 and does not inhibit 17 other protein 
kinases tested (Table 1). Paradoxically, however, incuba- 
tion of cells with ZM 336372 induces a huge activation of 
c-Raf (measured in the absence of this drug) that, in 3T3 
cells, is twice as great as that induced by the most potent 
agonist described previously (EGF). The simplest inter- 
pretation of this result is that cells have a feedback loop 
by which Raf suppresses its own activation, so that any 
inhibition of Raf is rapidly counterbalanced by its reacti- 
vation. This explanation is supported by the observation 
that ZM 336372 does not by itself induce the activation 
of MKKl or p42 MAPK, yet removing it causes an activa- 
tion of MKKl and p42 MAPK (Figure Sb). This implies 
that the cell does indeed contain high specific activity 
c-Raf that is prevented from activating its downstream 
substrate MKKl because of the presence of the inhibitor. 
The molecular mechanism by which this feedback loop 
operates appears to be novel, because it is not affected by 
inhibitors of protein kinase C, PtdIns 3-kinase or the 
MAP kinase cascade, and does not involve any change in 
the GTP loading of Ras. Our findings also raise the possi- 
bility that some substances reported to trigger the activa- 
tion of c-Raf in cells might really be inhibitors of this 
enzyme. Nevertheless, it cannot yet be excluded that 
ZM 336372 exerts its effect on c-Raf more indirectly by 
activating or inhibiting another unknown target allied to 
c-Raf activation. 
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Table 4 
Effect of mutating Met109 on the sensitivity of SAPKB to 
ZM 336372 and SB 203580. 
Residue at 109 
ZM 336372 SB 203560 
IC,, (PM) ICm W) 
Met No inhibition No inhibition 
Leu No inhibition 45 
Thr 0.5 0.3 
Ser 2 0.05 
Ala 10 0.01 
GIY 15 0.03 
Site-directed mutagenesis was used to change residue 109 in SAPK3 
from methionine to one of five other amino acids. The results with 
SB 203580 are taken from 1281. 
The finding that ZM 336372 inhibits SAPK2/p38 (Table 1) 
as well as c-Raf and B-Raf was intriguing because SB 
203580, a structurally unrelated compound that is a rela- 
tively specific inhibitor of SAPKZ/p38, also inhibits c-Raf 
[27]. Moreover, like ZM 336372, SB 203580 also induces 
an activation of c-Raf in cells (measured in the absence of 
the drug) [27]. In this paper we demonstrate that the 
binding sites for ZM 336372 and SB 203580 on SAPK2lp38 
(and presumably c-Raf and B-Raf) are likely to overlap 
because the single mutation of ThrlOb+Met abolishes 
inhibition by both compounds (Figure 8). A-Raf should 
also be sensitive to ZM 336372 because the critical threo- 
nine residue is also conserved in this isoform. In addition, 
other MAP kinase family members that are resistant to SB 
203580 because they possess methionine instead of threo- 
nine at this position, can be made sensitive to either ZM 
336372 or SB 203580 by changing this residue to threonine 
(Figure 8). Mutation to smaller residues (glycine and 
alanine), however, increases sensitivity to SB 203580, but 
decreases sensitivity to ZM 336372 (Table 4). We have 
excluded the possibility that SB 203580 triggers the activa- 
tion of c-Raf by binding to SAPK2/p38 rather than c-Raf 
itself, because the concentration of SB 203580 required to 
activate c-Raf in cells is higher than that required to inhibit 
SAPK2/p38. In addition, SB 203580 still induces the activa- 
tion of c-Raf in cells overexpressing an SB-203580-resistant 
mutant of SAPK2/p38 in which SB 203580 no longer pre- 
vents the activation of MAPKAP-KZ (a downstream target 
of SAPK2/p38) [27]. It could also be argued that the activa- 
tion of c-Raf by ZM 336372 is mediated by the binding of 
this drug to SAPK2/p38 and not c-Raf itself. This is 
unlikely, however, because ZM 336372 has a much greater 
effect on the activation of c-Raf than SB 203580 does, an 
observation that correlates with its greater potency against 
the isolated c-Raf enzyme rather than its somewhat lower 
potency against SAPK2/p38. 
Preincubation of cells with ZM 336372 does not trigger 
any activation of p42 MAPK (Figure 3), yet subsequent 
exposure to EGF in the continued presence of 
ZM 336372, which only increases c-Raf activity by a 
further ZO-30%, induces essentially complete activation of 
p42 MAPK (Figure 3) [22]. Similar results have been 
obtained with weaker activators of c-Raf in Swiss 3T3 
cells, such as PDGF and phorbol esters [22] that, after 
preincubation with ZM 336372, trigger an almost equally 
strong activation of p42 MAPK, even though no further 
activation of c-Raf is detectable under these conditions. 
The simplest interpretation of these results is that c-Raf 
activity is not rate limiting for the activation of MKKl and 
p42 MAPK by these agonists. It remains possible, 
however, that in addition to activating c-Raf p&r se, EGF 
and other agonists facilitate the activation of MKKl in 
additional ways, for example, by inducing the inhibition of 
a MKKl phosphatase or by activating kinase suppressor of 
Raf (KSR), another protein kinase that appears to be 
required for activation of the MAP kinase cascade but 
whose mechanism of action is unknown [32]. Whatever 
the explanation, however, these observations together 
with the failure of ZM 336372 to reverse the transformed 
phenotype of Ras or Raf-transformed cell lines (Table 2) 
suggests that compounds which inhibit the kinase activity 
of Raf might not be useful as anticancer drugs. 
Significance 
Nearly all aspects of cell life are controlled by the 
reversible phosphorylation of proteins and abnormal 
protein phosphorylation underlies a number of major 
diseases. There is therefore increasing interest in the 
development of specific inhibitors of protein kinases with 
therapeutic potential. Inappropriate activation of the 
Ras/MAP kinase cascade is a cause of cancer and, in the 
present study, we developed a potent and relatively selec- 
tive inhibitor of Raf, the protein kinase that lies at the 
head of this pathway. However, surprisingly, this 
inhibitor (ZM 336372) did not prevent activation of the 
Ras/MAP kinase cascade, nor did it reverse the pheno- 
type of Ras-transformed cell lines. Further investigation 
revealed that inhibition by ZM 336372 in cells was also 
accompanied by a remarkable activation of Raf. Thus 
Raf appears to suppress its own activation by a novel 
feedback loop, such that inhibition is always counterbal- 
anced by reactivation. These observations imply that 
some agonists reported to trigger the cellular activation 
of Raf might actually be inhibitors of this enzyme and 
that compounds which inhibit the kinase activity of Raf 
may not be useful as anticancer drugs. We also show 
that, although ZM 336372 did not inhibit 17 other 
protein kinases tested, it did inhibit stress-activated 
protein kinase 2a (SAPK2a) and SAPK2b (also called 
p38 and p38p), albeit less strongly. SAPK2a and 
SAPK2b are known to be inhibited relatively specifically 
by the anti-inflammatory drug SB 203580, and we have 
shown previously that SB 203580 inhibits Raf, although 
not as potently as SAPK2alp38 and SAPK2blp38P. 
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Interestingly, a point mutation in SAPK2alp38 that 
renders it insensitive to SB 203580 also made it insensi- 
tive to ZM 336372, and the reverse mutation that makes 
other SAPK family members sensitive to SB 203580 also 
made them sensitive to ZM 336372. This suggests that 
the binding sites for SB 203580 and ZM 336372 are 
likely to overlap, despite their dissimilarity in structure. 
Materials and methods 
Materials 
Ro 318220 was a kind gift from Dr D. Bradshaw (Roche Pharmaceuti- 
cal Company, Welwyn Garden City, UK), PD 98059 was purchased 
from Calbiochem and wortmannin and PMA from Sigma. These drugs 
were dissolved in dimethyl sulphoxide (DMSO) at concentrations of 
1 O-50 mM. They were either diluted appropriately in aqueous buffers 
just prior to use, or added directly to the cell culture media to achieve 
final concentrations of 100 nM to 50 PM. Control experiments con- 
tained the equivalent amounts of DMSO, which did not exceed 0.2% 
(v/v) in any experiment. This concentration did not affect the activity or 
activation of any protein kinase examined. EGF was purchased from 
Boehringer Mannheim and the monoclonal anti-H-Ras antibody 
(Y 13 259) from Oncogene Science Products. Antibodies against c-Raf 
[24], MAPKAP-Kl 1331 MKKl and p42 MAPK were raised in sheep at 
the Scottish Antibody Production Unit (Carluke, Lanarkshire, UK). The 
anti-MKKl antibody was raised against a peptide corresponding to 
residues 2-l 7 (PKKKPTPIQLNPAPDG) and the anti-p42 MAPK anti- 
body against the carboxy-terminal peptide (EETARFQPGYRS). All pep- 
tides were conjugated to both bovine serum albumin and keyhole 
limpet haemocyanin before injection and the antisera were affinity puri- 
fied on appropriate immobilised peptide affinity columns. 
Western blotting 
HCT 116 human colon carcinoma cells were obtained from ATCC 
(Manassas, Virginia, U.S.A.) MAPK antibody (Santa Cruz SC-94) was 
used according to the manufacturer’s instructions. 
Cell culture and stimulation 
Confluent mouse Swiss 3T3 fibroblasts, human 293 cells and monkey 
COS-1 cells were incubated for 18 h in DMEM containing 0.5% FCS. 
After treatment with growth factors or inhibitors as indicated, each 10 cm 
dish of cells was lysed in 0.4 ml of ice-cold Buffer A (20 mM Tris acetate, 
pH 7.5, 0.27 M sucrose, 1% (by mass) Triton X-100, 1 mM EDTA, 1 mM 
EGTA, 50 mM sodium fluoride, IO mM sodium P-glycerophosphate, 
5 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 0.1% (by 
vol) P-mercaptoethanol, 0.1 mM phenylmethylsulphonyl fluoride, 1 mM 
benzamidine, 5uglml leupeptin), and the lysates frozen immediately in 
liquid nitrogen and stored at -8O’C until use. H-ras and c-raf transformed 
NIH3T3 cells were cultured in DMEM containing 5% charcoal stripped 
FCS. After 5 days, morphology was scored by microscopic observation 
and growth monitored by trypsinisation and cell counting. 
lmmunoprecipitation of protein kinases 
c-Raf was immunoprecipitated from 400 ug ceil lysate protein, MKKl 
from 100 pg of cell lysate and p42 MAPK and MAPKAP kinase-1 from 
50 ug cell lysate protein using 5 ul of protein G-Sepharose conjugated 
to 4 pg of the appropriate antibody [24,33]. 
Assay of protein kinases 
c-Raf, MKKl and p42 MAPK 1241 and MAPKAP kinase-1 1331 were 
assayed as described previously. c-Raf activity was measured in a 
coupled assay containing MKKl, p42 MAPK and its substrate myelin 
basic protein (MBP). One unit of c-Raf activity was that amount which 
increased the activity of p42 MAPK by 1 unit/min. MKKl was assayed 
by the activation of bacterially expressed p42 MAPK 1241. One unit of 
MKKl activity (U) was that amount which increased the activity of p42 
MAPK by 1 unitlmin. One unit of MAPK activity was that amount which 
catalysed the phosphorylation of 1 nmol of MBP in 1 min. 
For the initial compound screen, assays were performed in microtitre 
plates in 50 ul buffer as described previously [24] and modified to a 
single step reaction containing 0.3U Raf, 0.5 pg GST-MKKl, 1 ug 
GST-p42 MAPK, 16 ug MBP and 0.3mCi-[y33P] ATP (30 PM). Assays 
were performed at room temperature for 90 min before being stopped 
by addition of 75 pl 200/o (v/v) phosphoric acid and captured on P30 
filtermats (Wallac, Milton Keynes, UK) using a microcell harvester. 
Filters were washed and counted as described previously. 
Measurement of guanine nucleotides bound to Ras 
Confluent Swiss 3T3 cells were incubated for 18 h in DMEM contain- 
ing 0.5% FCS, then for 1 h in phosphate-free DMEM before labelling 
for 4 h with 32P-orthophosphate (5 mCi per 10 cm dish). After stimula- 
tion, cells were washed with ice-cold 20 mM Tris/HCI pH 7.5, 150 mM 
NaCl and lysed in Buffer B (50 mM HEPES, pH 7.4, 100 mM NaCI, 
5 mM MgCI,, 1 mg/ml bovine serum albumin (BSA), 1 mM sodium 
phosphate, complete proteinase inhibitor cocktail (Boehringer 
Mannheim), 100 uM GTP, 100 pM GDP, 1 mM ATP) containing lo/, 
(by mass) Triton X-l 14 (Boehringer Mannheim)). Nuclei were removed 
by centrifugation for 5 min at 13,000 x g, and the supernatant incu- 
bated for 3 min at 37°C and centrifuged for 2 min at 13,000 x g to 
separate the Triton X-l 14 and aqueous phases. The detergent phase 
was diluted tenfold with Buffer B plus 0.5 M NaCI. The lysate was pre- 
cleared with protein G-Sepharose coupled to rabbit pre-immune 
serum (15 min) and Ras immunoprecipitated using 25 ul protein 
G-Sepharose beads coupled to 10 pg anti-H-Ras antibody (60 min). 
The immunoprecipitates were washed 8x with Buffer C (50 mM 
HEPES, pH 7.4, 500 mM NaCI, 5 mM MgCI,, 0.1% Triton X-l 00, 
0.005% SDS). GTP and GDP were eluted by incubation for 2 min at 
70°C in 2 mM EDTA, 2 mM DTT, 0.2% (by mass) SDS, 0.5 mM GDP, 
0.5 mM GTP and separated on polyethyleneimine (PEI) cellulose 
plates (Merck) developed in 1.2 M ammonium formate, 0.8 M HCI. 
Plates were autoradiographed and the radioactive spots cut out and 
analysed by Cerenkov counting 1341. 
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